1127563-71-6

Upstream product

• 1127563-68-1 6-(4-(4-fluorophenoxy)phenyl)pyridine-2-carbonitrile N-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 361437-00-5 (4-(4-fluorophenoxy)phenyl)boronic acid 
• 1578241-99-2 4-chloro-2-[4-(4-fluorophenoxy)phenyl]pyridine 
• 7379-35-3 4-chlorpyridine hydrochloride 
• 2402-98-4 2-cyanopyridine N-oxide 
• 55102-99-3 1-bromo-4-(4-fluorophenoxy) benzene 
• 371-41-5 4-Fluorophenol 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 100-70-9 2-Cyanopyridine 

Downstream Products

• 1127563-74-9 6-(4-(4-fluorophenoxy)phenyl)-4-morpholinopyridine-2-carbonitrile 
• 1367124-88-6 6-(4-(4-fluorophenoxy)phenyl)-4-((2-morpholinoethyl)amino)picolinamide 
• 1367127-58-9 C₂₀H₁₅FN₂O₃ 
• 1367127-60-3 C₂₀H₁₇FN₂O₄ 
• 1367126-66-6 C₂₄H₂₃FN₄O₂ 

Relevant academic research and scientific papers

Scope and limitation for FeSO4-mediated direct arylation of heteroarenes with arylboronic acids and its synthetic applications

FeSO4-mediated direct arylation of heteroarenes with arylboronic acids in the presence of K2S2O8 has been developed. A slow addition of an aqueous solution of an iron complex was crucial in the arylation. Scope and limitation of the heteroarenes and arylboronic acids are discussed. Furthermore, the direct arylation was applied to the formal total synthesis botryllazine B and sodium channel inhibitor.

PYRIDINE COMPOUNDS AND THE USES THEREOF

The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, A1, A2, E, G, Z1, and Z2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.